DrugDashboards

Market view

evolocumab · Injection, Solution

12 marketed package NDCs · 2 active manufacturers

Most dispensed: 140 mg/mL · Injection, Solution · #1 syringe/carton / 1 ml in 1 syringe · 140 mg/mL · Injection, Solution · #2 syringes/carton / 1 ml in 1 syringe

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately. The price has held steady around $281.89 per mL over the past year. Historically, drugs in this position went on to a new shortage within 90 days about 0.4% of the time — roughly 3× the typical drug (0.1%).

Price range and competition

RSS: changes for this drug

Every company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.

$0$100.00$200.00$300.00Jan 2019Sep 202602companies actively selling

Latest · Sep 2026 — typical price $281.89 · middle half $281.81$281.97 · full range $281.81$281.97 · 4 products · 2 companies

middle half of companies’ pricestypical (median) pricecompanies actively selling (bottom lane)Priced per mLSource: CMS NADAC
ⓘ How this was built
Data sources
  • CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
  • CMS Federal Upper Limit files (weighted AMP)
  • FDA NDC Directory (openFDA) — maker roster
Method

Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.

Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.

What changed in the last 90 days

Every detected change for evolocumab, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.

  • RepathaAug 19, 2026
    Price down
    NADAC $281.99444 → $281.96916 per unit (-0.01%)
  • RepathaAug 19, 2026
    Price up
    NADAC $281.79708 → $281.80579 per unit (0%)
  • RepathaAug 19, 2026
    Price up
    NADAC $281.79708 → $281.80579 per unit (0%)
  • RepathaAug 19, 2026
    Price down
    NADAC $281.99444 → $281.96916 per unit (-0.01%)
  • evolocumabJul 30, 2026
    Mfr entered
    Patheon Italia S.p.A. · evolocumab
  • evolocumabJul 30, 2026
    New product
    Patheon Italia S.p.A.
  • RepathaJul 29, 2026
    New product
    Amgen USA Inc.
  • RepathaJul 29, 2026
    New product
    Amgen USA Inc.
  • RepathaJul 29, 2026
    New product
    Amgen USA Inc.
  • RepathaJul 22, 2026
    Price up
    NADAC $281.69732 → $281.79708 per unit (+0.04%)

Same drug class

Other molecules FDA puts in PCSK9 Inhibitor, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.

Common questions

Is Evolocumab in shortage right now?
No. FDA does not currently list Evolocumab in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
Who makes Evolocumab?
2 companies have marketed Evolocumab in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
What does Evolocumab cost?
The typical pharmacy pays about $281.89 per mL, based on the most recent CMS NADAC survey of actual acquisition costs. That is what the pharmacy pays for the drug itself — not the cash price, and not what an insurer is billed.

All marketed products

Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.